Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313248 | 0.84 | CYP17A1 (0.46) | CYP17A1CYP3A4ACSS2PLAUPTPN1 | |
| SCHEMBL15385226 | 0.80 | CYP17A1 (0.41) | CYP17A1CYP3A4ACSS2PLAUPTPN1 | |
| SCHEMBL866079 | 0.79 | CYP17A1 (0.40) | CYP17A1CYP3A4ACSS2PLAUPTPN1 | |
| SCHEMBL313157 | 0.75 | CYP17A1 (0.45) | CYP17A1CYP3A4ACSS2PLAUPTPN1 | |
| SCHEMBL312979 | 0.75 | CYP17A1 (0.46) | CYP17A1CYP3A4ACSS2PLAUPTPN1 | |
| SCHEMBL4031099 | 0.74 | CYP17A1 (0.52) | CYP17A1CYP3A4ACSS2PTPN1 | |
| SCHEMBL313052 | 0.73 | CYP17A1 (0.43) | CYP17A1CYP3A4ACSS2PTPN1 | |
| SCHEMBL4025339 | 0.73 | CYP17A1 (0.53) | CYP17A1CYP3A4ACSS2PLAUPTPN1 | |
| SCHEMBL313418 | 0.71 | CYP17A1 (0.42) | CYP17A1CYP3A4ACSS2PTPN1 | |
| SCHEMBL4024970 | 0.69 | CYP17A1 (0.44) | CYP17A1CYP3A4ACSS2PLAUPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | CYP17A1 1/4885CYP3A4 136/4885ACSS2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.